KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accumulated Expenses: 2010-2018

Historic Accumulated Expenses for Biomarin Pharmaceutical (BMRN) over the last 9 years, with Dec 2018 value amounting to $149.9 million.

  • Biomarin Pharmaceutical's Accumulated Expenses rose 13.92% to $87.3 million in Q1 2019 from the same period last year, while for Mar 2019 it was $87.3 million, marking a year-over-year increase of 13.92%. This contributed to the annual value of $149.9 million for FY2018, which is 6.50% up from last year.
  • According to the latest figures from FY2018, Biomarin Pharmaceutical's Accumulated Expenses is $149.9 million, which was up 6.50% from $140.8 million recorded in FY2017.
  • Biomarin Pharmaceutical's Accumulated Expenses' 5-year high stood at $149.9 million during FY2018, with a 5-year trough of $45.5 million in FY2014.
  • Moreover, its 3-year median value for Accumulated Expenses was $140.8 million (2017), whereas its average is $133.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first dropped by 22.14% in 2014, then spiked by 109.65% in 2015.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Accumulated Expenses stood at $45.5 million in 2014, then surged by 109.65% to $95.3 million in 2015, then rose by 14.36% to $109.0 million in 2016, then climbed by 29.11% to $140.8 million in 2017, then climbed by 6.50% to $149.9 million in 2018.